AstraZeneca heartened by US FDA nod to antiplatelet medicine Brilinta
This article was originally published in Scrip
Executive Summary
AstraZeneca finally pulled off a US win for Brilinta (ticagrelor), with the FDA granting the OK on 20 July for the London drug maker to market the oral antiplatelet medicine as a therapy to reduce the rate of heart attack and cardiovascular death in adults with acute coronary syndrome (ACS) – an umbrella term for conditions that result from a reduction in blood flow to the heart muscle.